Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity [Yahoo! Finance]
Allurion Technologies, Inc. (ALUR)
Company Research
Source: Yahoo! Finance
5 min read In This Article ALUR ALUR-WS NATICK, Mass., February 18, 2025 BUSINESS WIRE )--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous studies have shown that 30% of patients discontinue GLP-1 therapy within the first month and 58% discontinue before reaching a clinically meaningful health benefit , due in part to side effects, dose escalation required for continued weight loss, and cost. Studies have previously demonstrated successful use of the Allurion Balloon in combination with short-term use of GLP-1 agonists. In a randomized, double-blind study, published in Obesity Surgery , patients treated
Show less
Read more
Impact Snapshot
Event Time:
ALUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALUR alerts
High impacting Allurion Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
ALUR
News
- Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 AdherenceBusiness Wire
- New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention AloneBusiness Wire
- Allurion Technologies (NYSE:ALUR) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $2.50 price target on the stock.MarketBeat
- Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight LossBusiness Wire
- Allurion Technologies Inc (ALUR) Q3 2025 Earnings Call Highlights: Strategic Restructuring and ... [Yahoo! Finance]Yahoo! Finance
ALUR
Earnings
- 5/14/25 - Beat
ALUR
Sec Filings
- 12/5/25 - Form 4
- 12/2/25 - Form 144
- 11/26/25 - Form D
- ALUR's page on the SEC website